| Name | Title | Contact Details |
|---|
United Medical Systems is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scrubs and Beyond is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Creganna is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Permobil founder Dr. Per Uddén believed that helping individuals achieve the greatest level of independence is a basic human right and, for over 50 years, that has been the driving force behind our innovative assistive technology. We are passionate about understanding our users` needs and helping them live life to the fullest. We are a global leader in trusted healthcare solutions for power and manual wheelchairs, seating and positioning products, and power assist. Permobil is part of Patricia Industries, a subsidiary of Investor AB and is headquartered in Sweden. Permobil has 1600 team members in more than 15 countries around the world. For more information regarding the company`s storied history and complete product line visit permobil.com. Permobil Group is owned by Investor AB and the global leader in Advanced Rehab Technology. We are present in more than 17 countries with 1 600 employees and have an annual turnover of more than SEK 4 billion. Our major brands are Permobil, TiLite and ROHO, with more to come. We are continuously growing by entering new geographical markets and adding new technologies and products, to further support the community of people with disabilities.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.